Berlin, Germany, March 30, 2009. – BIOTRONIK GmbH & Co KG, a leading manufacturer of implantable cardiac devices, such as Lumax 540 implantable cardioverter defibrillators (ICDs), and pioneer in wireless remote monitoring technology, today announced the global launch of the new BIOTRONIK Home Monitoring®. With its intelligent traffic light system, BIOTRONIK Home Monitoring provides efficient and convenient remote monitoring of patients with implantable cardiac devices. It is proven to ensure patient safety through earlier detection of serious arrhythmic events with the potential to significantly reduce the number of clinic follow-up visits.1
The new BIOTRONIK Home Monitoring system is based on more than eight years of experience in remote monitoring technology and extensive research among both physicians and patients. BIOTRONIK Home Monitoring is available across the entire product portfolio of pacemakers, ICDs and cardiac resynchronization therapy (CRT) devices allowing physicians to remotely monitor their patients’ clinical and device status at any time and from anywhere in the world.
Using an intuitive, red-yellow-coded traffic light concept, BIOTRONIK Home Monitoring quickly and easily identifies patients with the most clinically relevant events to streamline clinic workflow; ensuring efficient use of clinic time by reducing unnecessary in-office follow-ups and so improving patient care. Daily as well as trend patient and device information, is automatically evaluated and prioritized through the intelligent traffic light system, and conveniently presented in the CardioReport®. This status summary on the BIOTRONIK Home Monitoring secure website enables physicians to quickly review the most important information at a glance.
“BIOTRONIK has set a milestone with the launch of its new Home Monitoring system: an advanced, evidence-based remote monitoring technology, with early detection of arrhythmias and other clinically relevant events, delivering simplified yet safe and efficient patient care.” said Professor, Dr Pedro Brugada, Head, Heart Rhythm Management Institute, Cardiology Department, Free University of Brussels, Belgium.
Moreover, this fully automatic system enables early detection of clinically relevant changes in patient or device status, allowing prompt intervention to prevent further worsening in a patient’s condition. In these cases of important status changes, BIOTRONIK Home Monitoring generates an alert notification via email, SMS or fax to the physician. BIOTRONIK Home Monitoring has been proven to enable physicians to identify patients who require attention earlier.1,2 The unique CardioMessenger®, patient device, gives patients freedom to be completely mobile while wirelessly transmitting important clinical and device status information to the BIOTRONIK Home Monitoring secure website for physician evaluation.
TRUST (Lumax-T/Lumos-T safely RedUceS rouTine office device follow-up), a multi-center, prospective, randomized controlled trial has proved that BIOTRONIK Home Monitoring is as safe and effective as conventional in-office ICD follow-up.1 Dr Niraj Varma, Cardiac Pacing & Electrophysiology, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, USA and TRUST Principal Investigator, explained: “TRUST demonstrates that BIOTRONIK Home Monitoring significantly reduces the need for hospital visits by almost a half, and at the same time, ensures follow-up surveillance and enables prompt medical evaluation of critical cardiac events. This automatic remote device monitoring system offers an opportunity to improve patient care”. This evidence-base will grow even further with the completion of BIOTRONIK’s ongoing remote patient management clinical trials.
Furthermore, the advanced functionality of BIOTRONIK Home Monitoring and its intelligent workflow tools facilitate the establishment of unique collaborative care networks, allowing multiple clinics and physicians to simultaneously manage an individual patient. Such a collaborative approach enhances the quality-of-life and care of patients with cardiovascular disease as well as the workflow efficiencies within one or more clinics.
“We invite physicians from around the world to try the only clinically proven, wireless remote monitoring technology designed to enhance patient care and optimize clinic resources. During the initial roll out phase many physicians have already confirmed the unique benefits of the new BIOTRONIK Home Monitoring, validating BIOTRONIK’s extensive investment in taking our pioneering innovation to the next level. The significant enhancements to BIOTRONIK Home Monitoring are offered as a straightforward and simple solution”, commented, Marlou Janssen, Vice President Global Marketing and Sales, Cardiac Rhythm Management, BIOTRONIK. ”The global launch of the new BIOTRONIK Home Monitoring reaffirms our leadership position in telecardiology for patients with cardiac devices.”
1. N. Varma et al. Evaluation of efficacy and safety of remote monitoring for ICD follow-up: the TRUST trial. Circulation 2008;118;2309-2317, Abstract 4078
2. A. Lazarus. Remote, wireless, ambulatory monitoring of implantable pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy systems: analysis of a worldwide database (AWARE study), PACE 2007, 30:S2–S12
Today, more than 150,000 BIOTRONIK Home Monitoring systems have been implanted, in more than 50 countries worldwide, helping to optimize patient care management in more than 3,000 clinics.
As one of the world’s leading cardiovascular medical device companies, with several million implanted devices, BIOTRONIK is represented in over 100 countries with its global workforce of more than 4500 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.